Discover how molecular glue degraders harness the ubiquitin–proteasome system to destroy oncogenic proteins once considered “undruggable.” Learn what molecular glues are, how they differ from traditional inhibitors, and why they’re poised to transform precision oncology.
Discover how AI-designed small molecule drugs are reshaping drug discovery. Learn how deep learning, generative models, and structure-based machine learning accelerate target-specific molecule design, optimize ADMET, and compress early discovery timelines from years to months.
Learn what AI-designed small molecule drugs are and how machine learning, deep learning, and generative models are revolutionizing small molecule discovery by exploring chemical space, optimizing ADMET, and accelerating R&D timelines.
Learn what targeted protein degraders (TPDs) are, how PROTACs harness the ubiquitin–proteasome system to eliminate disease-causing proteins, why degradation can outperform traditional inhibition, and how these therapies are advancing into clinical trials.
Explore how quantum-ready small molecule oncology drugs are transforming precision cancer therapy. Learn how AI-driven de novo design, ultra-large virtual screening, and quantum-inspired simulations enable mutation-aware, network-level, and ADMET-optimized cancer drug discovery.
Learn what proteolysis-targeting chimeras (PROTACs) are, how they work as small-molecule protein degraders, and why they outperform classic inhibitors by accessing undruggable targets, driving deep protein knockdown, and enabling next-generation cancer therapies like ARV-110.
Discover how AI and machine learning are revolutionizing oral small molecule drug discovery—from target-informed data assembly and generative design to in silico ADME profiling—enabling faster, more selective, and orally bioavailable small-molecule therapies.
Discover how AI and machine learning are transforming small molecule drug discovery—from high-throughput screening and chemical intuition to data-driven generative models that design clinically viable candidates in record time.
Learn how molecular glue small molecules rewire protein–protein interactions, enable targeted protein degradation, and unlock “undruggable” targets in oncology, neurology, and immunology. Explore their mechanism, history from thalidomide to rational design, and role in AI-driven drug discovery.
Discover how next‑generation KRAS inhibitors are overturning the “undruggable” myth in oncology. Learn why KRAS was so hard to target, how covalent KRAS G12C inhibitors like sotorasib and adagrasib work, and what this revolution means for personalized cancer treatment.